公开(公告)号：WO2017011685A1

公开(公告)日：2017-01-19

申请号：PCT/US2016/042330

申请日：2016-07-14

Applicant: CELATOR PHARMACEUTICALS, INC.

Inventor： WAN, Leon ,  LUI, Winnie ,  TARDI, Paul ,  MAYER, Lawrence

IPC: A61K9/00

CPC classification number: A61K9/5192 ,  A61K9/0019 ,  A61K9/5153 ,  A61K47/554

Abstract: Nanopaiticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.

Abstract translation: 本文所述的纳米微粒组合物包含与施用这些治疗剂的游离形式的组合时观察到的效果相比增强的治疗效果的治疗剂前药的组合。

公开(公告)号：WO2008101214A2

公开(公告)日：2008-08-21

申请号：PCT/US2008054168

申请日：2008-02-15

Applicant: CELATOR PHARMACEUTICALS INC ,  LOUIE ARTHUR ,  SWENSON CHRISTINE ,  MAYER LAWRENCE ,  JANOFF ANDREW

Inventor： LOUIE ARTHUR ,  SWENSON CHRISTINE ,  MAYER LAWRENCE ,  JANOFF ANDREW

IPC: A61K31/70 ,  A61K9/127 ,  A61P35/00

CPC classification number: A61K31/70 ,  A61K9/0019 ,  A61K9/127 ,  Y10T436/143333

Abstract: Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

Abstract translation: 本文提供了通过施用包含固定的非拮抗摩尔比的阿糖胞苷和蒽环霉素的药物组合物来治疗癌症的方法。 这些方法在治疗晚期血液癌症或增殖性疾病的患者中特别有用。

公开(公告)号：WO2006081354A3

公开(公告)日：2006-08-03

申请号：PCT/US2006/002782

申请日：2006-01-26

Applicant: CELATOR PHARMACEUTICALS, INC. ,  TARDI, Paul ,  MAYER, Lawrence ,  CABRAL-LILLY, Donna

Inventor： TARDI, Paul ,  MAYER, Lawrence ,  CABRAL-LILLY, Donna

IPC: A61K9/127

Abstract: The invention relates to a method for reducing the polydispersity of a population of gel-phase lipid-based delivery vehicles.

公开(公告)号：WO2020068979A1

公开(公告)日：2020-04-02

申请号：PCT/US2019/052952

申请日：2019-09-25

Applicant: CELATOR PHARMACEUTICALS, INC. ,  CHEUNG, Ronald ,  FADERL, Stefan

Inventor： CHEUNG, Ronald ,  FADERL, Stefan ,  WANG, Qi

IPC: A61K31/704 ,  A61K31/7068 ,  A61K9/127 ,  A61K39/395 ,  A61P35/02

Abstract: The invention relates to compositions and methods for treating patients with hematological proliferative disorders who are ineligible for treatment with standard intensive chemotherapy, using low intensity treatment with CPX-351, a liposomal composition of daunorubicin and cytarabine.

公开(公告)号：WO2009097011A1

公开(公告)日：2009-08-06

申请号：PCT/US2008/073185

申请日：2008-08-14

Applicant: CELATOR PHARMACEUTICALS, INC. ,  TARDI, Paul ,  JOHNSTONE, Sharon ,  MAYER, Lawrence

Inventor： TARDI, Paul ,  JOHNSTONE, Sharon ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K31/4745 ,  A61K31/555 ,  A61K33/24

Abstract: Compositions which comprise liposomes having controlled release of a platinum agent are useful in achieving enhanced therapeutic effects particularly when these drugs are administered in combination with other therapeutic agents.

Abstract translation: 包含具有铂剂的受控释放的脂质体的组合物可用于实现增强的治疗效果，特别是当这些药物与其它治疗剂组合施用时。

公开(公告)号：WO2007076117A3

公开(公告)日：2007-11-01

申请号：PCT/US2006049245

申请日：2006-12-22

Applicant: CELATOR PHARMACEUTICALS INC ,  DICKO AWA ,  TARDI PAUL ,  MAYER LAWRENCE ,  JOHNSTONE SHARON

Inventor： DICKO AWA ,  TARDI PAUL ,  MAYER LAWRENCE ,  JOHNSTONE SHARON

IPC: A61K9/127

CPC classification number: A61K9/1278

Abstract: Provided herein are liposomal compositions comprising a therapeutic agent having a protonatable amino group and a secondary or tertiary amine, and methods for encapsulating such therapeutic agents. In one aspect, the present invention relates to liposomal formulations comprising irinotecan in a triethanolamine solution, and optionally comprising copper gluconate, and methods for preparing the same.

Abstract translation: 本文提供了包含具有可质子化氨基和仲或叔胺的治疗剂的脂质体组合物，以及用于包封这些治疗剂的方法。 一方面，本发明涉及包含三乙醇胺溶液中的伊立替康和任选地包含葡萄糖酸铜的脂质体制剂及其制备方法。

公开(公告)号：WO2007035783A2

公开(公告)日：2007-03-29

申请号：PCT/US2006/036569

申请日：2006-09-19

Applicant: CELATOR PHARMACEUTICALS, INC. ,  JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  TARDI, Paul ,  HARASYM, Troy ,  MAYER, Lawrence

Inventor： JOHNSTONE, Sharon ,  HARVIE, Pierrot ,  TARDI, Paul ,  HARASYM, Troy ,  MAYER, Lawrence

IPC: A61K9/127

CPC classification number: A61K9/127

Abstract: Compositions which comprise delivery vehicles having stably associated therewith a cytidine analog and a platinum agent are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered.

Abstract translation: 包含稳定与胞苷类似物和铂剂相关的递送载体的组合物在施用这些药物的组合时可用于实现增强的治疗效果。

公开(公告)号：WO2006014626A3

公开(公告)日：2006-10-05

申请号：PCT/US2005025549

申请日：2005-07-19

Applicant: CELATOR PHARMACEUTICALS INC ,  UNIV PRINCETON ,  MAYER LAWRENCE D ,  PRUD HOMME ROBERT K ,  ALLEN CHRISTINE J ,  SAAD WALID S

Inventor： MAYER LAWRENCE D ,  PRUD HOMME ROBERT K ,  ALLEN CHRISTINE J ,  SAAD WALID S

IPC: A61K31/74 ,  A61K31/77

CPC classification number: A61K47/482 ,  A61K8/85 ,  A61K9/5153 ,  A61K45/06 ,  A61K47/22 ,  A61K47/48107 ,  A61K47/48192 ,  A61K47/551 ,  A61K47/552 ,  A61K47/58 ,  A61K47/59 ,  A61K47/593 ,  A61K47/60 ,  A61K47/6935 ,  A61K2800/57 ,  A61Q17/04 ,  B82Y5/00

Abstract: Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.

Abstract translation: 通过两亲性共聚物稳定并且包含至少一个与疏水部分结合的活性物质的颗粒构建物在体外和体内环境中均提供活性物质的持续释放。

公开(公告)号：WO2006014626A2

公开(公告)日：2006-02-09

申请号：PCT/US2005/025549

申请日：2005-07-19

Applicant: CELATOR PHARMACEUTICALS, INC. ,  THE TRUSTEES OF PRINCETON UNIVERSITY ,  MAYER, Lawrence, D. ,  PRUD'HOMME, Robert, K. ,  ALLEN, Christine, J. ,  SAAD, Walid, S.

Inventor： MAYER, Lawrence, D. ,  PRUD'HOMME, Robert, K. ,  ALLEN, Christine, J. ,  SAAD, Walid, S.

IPC: A61K9/14

CPC classification number: A61K47/482 ,  A61K8/85 ,  A61K9/5153 ,  A61K45/06 ,  A61K47/22 ,  A61K47/48107 ,  A61K47/48192 ,  A61K47/551 ,  A61K47/552 ,  A61K47/58 ,  A61K47/59 ,  A61K47/593 ,  A61K47/60 ,  A61K47/6935 ,  A61K2800/57 ,  A61Q17/04 ,  B82Y5/00

Abstract: Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.

Abstract translation: 通过两亲性共聚物稳定并且包含至少一种与疏水部分偶联的活性物质的微粒构建体在体内和体外都提供了活性物质的持续释放， I>的环境。

公开(公告)号：WO2020123481A1

公开(公告)日：2020-06-18

申请号：PCT/US2019/065440

申请日：2019-12-10

Applicant: CELATOR PHARMACEUTICALS INC.

Inventor： HUMPHREYS, Robin ,  TARDI, Paul ,  WAN, Leon ,  LIBOIRON, Barry

IPC: A61K9/00 ,  A61K9/14 ,  A61K9/51 ,  A61K31/337 ,  A61K47/34

Abstract: The invention relates to compositions and methods for improved delivery of combinations of therapeutic agents. More particularly, the invention concerns delivery systems which provide combinations of taxanes and mTOR inhibitors and derivatives thereof as well as methods of treating cancer using the same.